Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

Autor: Gap Hospers, M Franken, A.C.J. van Akkooi, H.M. Westgeest, Ellen Kapiteijn, Marye J Boers-Sonderen, R van Rijn, Mieke J. Aarts, A.J.M. van den Eertwegh, F van den Berkmortel, J.W.B. de Groot, Michel W.J.M. Wouters, B Leeneman, C.A. Uyl-de Groot, Karijn P M Suijkerbuijk, J.B.A.G. Haanen, A.A.M. Van der Veldt, Djura Piersma
Přispěvatelé: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Medical oncology, Internal medicine, AII - Cancer immunology, Epidemiology and Data Science, CCA - Cancer Treatment and quality of life, Health Technology Assessment (HTA), Pathology, Surgery, Immunology, Erasmus School of Economics, Medical Oncology, Erasmus School of Social and Behavioural Sciences, Psychiatry, Radiology & Nuclear Medicine, RISBO
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: ESMO Open, 6(6):100320. BMJ PUBLISHING GROUP
ESMO Open, 6(6):100320. BMJ Publishing Group
Esmo Open, 6, 6
Franken, M G, Leeneman, B, Aarts, M J B, van Akkooi, A C J, van den Berkmortel, F W P J, Boers-Sonderen, M J, van den Eertwegh, A J M, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, van der Veldt, A A M, Westgeest, H M, Wouters, M W J M, Haanen, J B A G & Uyl-de Groot, C A 2021, ' Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs ', ESMO OPEN, vol. 6, no. 6, 100320 . https://doi.org/10.1016/j.esmoop.2021.100320
ESMO OPEN, 6(6):100320. BMJ Publishing Group
Esmo Open, 6
ESMO Open
ISSN: 2059-7029
Popis: Background The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs. Materials and methods Data on survival and health care resource use were retrieved from the Dutch Melanoma Treatment Registry. The Kaplan–Meier method was used to estimate overall survival. Health care costs and budget impact were computed by applying unit costs to individual patient resource use. All outcomes were stratified by year of diagnosis. Results Baseline characteristics were balanced across cohort years. The percentage of patients receiving systemic treatment increased from 73% in 2013 to 90% in 2018. Patients received on average 1.85 [standard deviation (SD): 1.14] lines of treatment and 41% of patients received at least two lines of treatment. Median survival increased from 11.8 months in 2013 [95% confidence interval (CI): 10.7-13.7 months] to 21.1 months in 2018 (95% CI: 18.2 months-not reached). Total mean costs were €100 330 (SD: €103 699); systemic treatments accounted for 84% of the total costs. Costs for patients who received systemic treatment [€118 905 (SD: €104 166)] remained reasonably stable over the years even after the introduction of additional (combination of) novel drugs. From mid-2013 to 2018, the total budget impact for all patients was €452.79 million. Conclusion Our study shows a gain in survival in the era of novel targeted and immunotherapeutic drugs. These novel drugs came, however, along with substantial health care costs. Further insights into the cost-effectiveness of the novel drugs are crucial for ensuring value for money in the treatment of patients with metastatic melanoma.
Highlights • The median survival of patients with metastatic melanoma increased from 11.8 months in 2013 to 21.1 months in 2018. • The gain in survival came along with substantial health care costs; health care costs were on average €100 300 per patient. • Costs were much higher for patients with systemic treatment (€118 905) than for patients without systemic treatment (€8316). • Costs for patients who received systemic treatment remained stable even after the introduction of additional novel drugs. • Insights into the cost-effectiveness of the novel drugs are crucial for ensuring value for money in metastatic melanoma.
Databáze: OpenAIRE
Externí odkaz: